In a report issued on January 11, David Turkaly from JMP Securities maintained a Buy rating on AxoGen (AXGN – Research Report), with a price target of $20.00. The company's shares closed last Thursday at $9.25, close to its 52-week low of $8.48. According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 7.6% and a 46.0% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics. AxoGen has an analyst consensus of Strong Buy, with a price target consensus of $25.33, implying a 169.5% upside from current levels.
https://www.tipranks.com/news/blurbs/axogen-axgn-receives-a-buy-from-jmp-securities?utm_source=advfn.com&utm_medium=referral